Interferon alpha receptor 1 antibodies and their uses

Details Interferon alpha receptor 1 antibodies and their uses Interferon alpha receptor 1 antibodies and their uses

2005-06-20

2010-02-16

Woodward, Cherie M (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S388220

Reexamination Certificate

active

07662381

ABSTRACT:
The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

REFERENCES:
patent: 5516515 (1996-05-01), Vellucci et al.
patent: 5731169 (1998-03-01), Mogensen et al.
patent: 5861258 (1999-01-01), Mogensen et al.
patent: 5886153 (1999-03-01), Mogensen et al.
patent: 5889151 (1999-03-01), Mogensen et al.
patent: 5919453 (1999-07-01), Benoit et al.
patent: 6458932 (2002-10-01), Novick et al.
patent: 6713609 (2004-03-01), Chuntharapai et al.
patent: 6787634 (2004-09-01), Benoit et al.
patent: 7179465 (2007-02-01), Benoit et al.
patent: 7465451 (2008-12-01), Benoit et al.
patent: 2003/0044410 (2003-03-01), Skurkovich et al.
patent: 2003/0166228 (2003-09-01), Chuntharapai et al.
patent: 2004/0067888 (2004-04-01), Tovey et al.
patent: 2005/0152901 (2005-07-01), Pickford et al.
patent: 2005/0208041 (2005-09-01), Cardarelli et al.
patent: 2007/0014724 (2007-01-01), Witte et al.
patent: 0369877 (1990-05-01), None
patent: 0563487 (1993-10-01), None
patent: WO 91/05862 (1991-05-01), None
patent: WO93/20187 (1993-10-01), None
patent: WO94/14467 (1994-07-01), None
patent: WO95/07716 (1995-03-01), None
patent: WO 97/41229 (1997-11-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/39211 (1999-08-01), None
patent: WO 00/53635 (2000-09-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 01/54721 (2001-08-01), None
patent: WO 01/55215 (2001-08-01), None
patent: WO 02/43428 (2002-06-01), None
patent: WO 02/43478 (2002-06-01), None
patent: WO 02/066649 (2002-08-01), None
patent: WO 2004/093908 (2004-11-01), None
Eid et al., European Cytokine Network. Dec. 2000; 11(4):560-73.
Goldman et al., J Interferon and Cytokine Research. 1999; 19:15-26.
Lu et al., J lmmunol. Feb. 15, 1998;160(4):1782-8.
Gahring et al., Autoimmunity. 1998; 28:243-248.
Pritsch et al., British J Haematol. 1999; 107:616-624.
Li et al., J Mol Biol. Mar 1, 1996;256(3):577-89.
Miller et al., J Rheumatol. Dec. 1995;23(12)2132-9, Abstract Only.
Martin et al., J lmmunol. Jun. 15, 1994; 152(12)5988-96, Abstract Only.
Scott et al., J Immunol. Dec. 1991; 147(11):4007-4013.
UniProt Accession No. P17181, INAR1—Human.
Lederman et al. Mol Immunol. 1991;28:1171-1181.
Li et al. PNAS USA. 1980; 77:3211-3214.
Fishwild et al., Nature Biotechnology. 1996;14:845-851.
Mayo et al., Stats Med. 1999;18:223-231.
Ohlin et al., Mol Immunol. May-Jun. 1996;33(7-8):583-92, Abstract only.
Lu et al., (J Immunol. 1998. 160:1782-1788).
Geysen et al., (J Mol Recog. 1988;1(1):32-41).
Short et al., (Protein Engineering. 2001;14(4):287-296).
Chen et al., (J Exp Med. Sep. 1, 1992;176:885-866).
Lewerenz et al., (J Mol Biol. Sep. 25, 1998;282(3):585-599).
Chen, et al., EMBO J. 1993; 12:811-820.
Cook et at, J Biol Chem, 1996;271:13448.
Cutrone and Langer, J Biol Chem. 2001;276:17140.
Fishwild et al., Nature Biotechnology 1996;14:845-851.
Foulis et al., Lancet. 1987;2:1423.
Hardy et al., Blood. 2001;97:473.
Hooks et al., Arthritis Rheum. 1982;25:396.
Lewerenz et at, J Mol Biol. 1998;282:585.
Lonberg et al., Nature. 1994;368(6474):856-859.
Novick et al., Cell. 1994;77:391.
Santini et al., J Exp Med. 2000;191:1777.
Streuli et al., Proc Natl Acad Sci USA. 1981;78:2848.
Uze et al. Cell. 1990;225.
Goldman et al., “Characterization Of Antihuman IFNAR-1 Monclonal Antibodies: Epitope Localization and Functional Analysis,” Journal of Interferon And Cytokine Research, 19:15-26 (1999).
Abramovich, et al., 1992, “Human IFN-ALPHA Receptor Detected by Two Monoclonal Antibodies,”Journal of Interferon Research, vol. 12, No. Suppl 1.: p. S217.
Benizri, et al., 1998, “Prolonged Allograft Survival In Cynomolgus Monkeys Treated With A Monoclonal Antibody To The Human Type I Interferon Receptor And Lowdoses Of Cyclosporine,”Journal of Interferon and Cytokine Research, vol. 18: p. 273-284.
Benoit, et al., 1993, “A Monoclonal Antibody To Recombinant Human IFN-ALPHA Receptor Inhibits Biologic Activity Of Several Species of Human IFN-ALPHA, IFN-BETA, and IFN-ONIEGA. Decection Of Heterogeneity Of The Cellular Type I IFN Receptor,”Journal of Immunology, vol. 150, No. 3: p. 707-716.
Colamonici, et al., 1990, “Characterization Of Three Monoclonal Antibodies That Recognize The Interferon ALPHA2 Receptor,”Proceedings of the National Academy of Sciences of USA, vol. 87, No. 18: p. 7230-7234.
Constantinescu, et al., 1994, “Role Of Interferon ALPHA/BETA Receptor Chain 1 In The Structure and Transmembrane Signaling Of The Interferon ALPHA/BETA Receptor Complex,”Proceedings of the National Academy of Sciences of USA, vol. 91, No. 20: 9602- 606.
Novick, et al., 2000, “The Neutralization Of Type I IFN Biologic Actions By Anti-IFNAR-2 Monoclonal Antibodies Is Not Entirely Due To Inhibition Of Jak-Stat Tyrosine Phosphorylation,”Journal of Interferon and Cytokine Research, vol. 20, No. 11: p. 971-982.
Aguet et al., “Interferon 5” Ed. I. Gresser p. 1-22, Academic Press, London (1983).
Amin et al., “Innovations in Pharmaceutical Technology,” Samedan Ltd, publishers, Jun. 2002.
Arvin AM and Miller JJ 3rd, “Acid labile alpha-interferon in sera and synovial fluids from patients with juvenile arthritis,” Arthritis Rheum. May 1984;27(5):582-5.
Blanco P, et al., “Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus,” Science. Nov. 16, 2001;294(5546):1540-3.
Branca AA “Bovine spleen, a convenient source for purifying a type I interferon receptor,” J. Interferon Res. 7(1):77-85 (1987).
Brinkmann V, et al., “Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells,” J Exp Med. Nov. 1, 1993;178(5):1655-63.
Brown M, et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?” J Immunol. May 1, 1996;156(9):3285-91.
Casset F, et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem Biophys Res Commun. Jul. 18, 2003;307(1):198-205.
Chuntharapai A, et al., “Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE,” Cytokine. Sep. 7, 2001;15(5):250-60.
Cohen RD, “Evolving medical therapies for ulcerative colitis,” Curr Gastroenterol Rep. Dec. 2002;4(6):497-505.
Colamonici et al, “Characterization of three monoclonal antibodies that recognize the interferon alpha 2 receptor,” Proc. Natl. Acad. Sci USA 87(18):7230-34 (1990).
Colman PM, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol. Jan. 1994;145(1):33-6.
Corssmit EP, et al., “Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans,” Clin Exp Immunol. Feb. 1997;107(2):359-63.
Deavin AJ, et al., “Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens,” Mol Immunol. Feb. 1996;33(2):145-55.
Dunbar BS and Schwoebel ED, “Preparation of polyclonal antibodies,” Methods in Enzymology (1990);182:663-70.
Eid et al, J. Interferon Res. 7(6):762 (1987).
Eid et al, Biochem. Biophys. Acta 1034(1):114-117 (1990).
Eid et al., “Characterization of a Domain of Human Type I Interferon Receptor Protein Involved in Ligand Binding”, J. Interferon Cytokine Research,

Affiliated with

Also associated with

Rating

Interferon alpha receptor 1 antibodies and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon alpha receptor 1 antibodies and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon alpha receptor 1 antibodies and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176793